1. Scrip
  2. >>Focus On Asia

Unilab Of Philippines Gains Foothold In Myanmar For Latest Expansion

Philippines drug maker United Laboratories has expanded beyond its borders to 10 Asian nations.

United Laboratories, a Philippines drug maker, has expanded beyond its borders to 10 Asian nations where it has a presence. One of the nation’s with a Unilab presence is Myanmar where the country manager also is vice president of the firm’s International Operations Division. Aristotle Dimitui, who joined Unilab in 1993, said in an interview he set up United Pharmaceutical in Myanmar with four branded products, including its leading paracetamol-based drugs Alaxan for pain relief and Decolgen for colds and influenza. Myanmar is the second-largest nation in Asia, but Dimitui said penetrating a country largely isolated from the rest of the world relied on the trust he built with local physicians to gain acceptance. (Click here for more

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

Korea Q2 Roundup: Global Sales, License Income Boost Yuhan, GC

 
• By Jung Won Shin

Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

More from Scrip

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Can Bayer’s Pharmaceuticals Division Help It Weather A Perfect Storm?

 
• By Aakash Babu

Bayer continues to keep faith in its pharmaceuticals business despite a plethora of problems for the wider group with job cuts, continued debt concerns and ongoing glyphosate litigation claims.

BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam

 
• By Manas Mishra

Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.